Alphyn Biologics, a clinical-stage dermatology company, has announced promising interim findings from the Phase 2a trial of their topical treatment, AB-101a, for atopic dermatitis (AD) with secondary bacterial infection. The results indicate that AB-101a is effectively addressing all efficacy and safety measures across mild, moderate, and severe cases of AD. This therapeutic candidate is successfully eliminating AD infections and managing flare-ups caused by bacteria on the skin. It is also reducing itchiness and demonstrating improvements in AD scores. These encouraging interim results were presented at The Society for Pediatric Dermatology annual meeting.
The multi-site Phase 2a trial program has completed enrollment with a total of 19 patients. The interim evaluation included results from 7 to 10 patients. Notably, 80% of patients experienced a significant improvement in itch score by at least 4 points, while 90% showed an EASI score improvement of at least 50%. Furthermore, 40% of participants saw a reduction in disease severity according to the IGA score, with 64% achieving clear or nearly clear skin.